Sanofi SA / ADEL, Inc.

Alzheimer's disease

6.9M US cases/yr · $8.5B Global Alzheimer's therapy market 2024 (~$8.5B, projected $15B+ by 2030 with DMTs) · 360000 US annual AD care cost ($360B)

Disease Overview

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by extracellular amyloid-beta plaques, intracellular neurofibrillary tangles of hyperphosphorylated tau, synaptic dysfunction, and neuronal death. It is the leading cause of dementia, affecting approximately 6.9 million Americans aged 65+ in 2024, projected to rise to 13.8 million by 2050 as the population ages. AD accounts for 60-80% of dementia cases and is the 5th leading cause of death in Americans over 65. The direct care cost to the US healthcare system exceeds $360 billion annually. Therapeutic progress has historically been slow. The first disease-modifying therapies — Leqembi (lecanemab, Biogen/Eisai, approved July 2023) and Kisunla (donanemab, Lilly, approved July 2024) — target amyloid plaques and produced modest slowing of cognitive decline with significant ARIA (amyloid-related imaging abnormalities) safety signals requiring MRI monitoring. Unmet need remains vast: earlier intervention, broader eligibility, non-anti-amyloid mechanisms (particularly anti-tau), and safer tolerability profiles are all active areas. Tau pathology correlates more tightly than amyloid with cognitive decline and neurodegeneration, making anti-tau approaches (antibodies, ASOs, small molecules) a strategic priority. ADEL-Y01 is a humanized monoclonal antibody selectively targeting tau acetylated at lysine 280 (acK280), a post-translational modification enriched in pathological tau.

Competitive Landscape

The Alzheimer's competitive landscape has bifurcated between symptomatic and disease-modifying therapies. Symptomatic agents include donepezil (Aricept, cholinesterase inhibitor), rivastigmine (Exelon), galantamine (Razadyne), and memantine (Namenda, NMDA receptor antagonist) — all now generic with commoditized pricing. Anti-amyloid disease-modifying therapies (DMTs) now dominate the DMT segment: Leqembi (lecanemab, Eisai/Biogen, approved July 2023) and Kisunla (donanemab, Eli Lilly, approved July 2024) are the two approved monoclonal antibodies targeting aggregated amyloid-beta; Aduhelm (aducanumab, Biogen) was discontinued in early 2024 following reimbursement and commercial challenges. Anti-tau pipelines represent the next strategic battleground given tau's tighter correlation with cognitive decline. Direct competitors to ADEL-Y01 include bepranemab (UCB/Roche, anti-tau antibody, Phase II), E2814 (Eisai, anti-tau MTBR domain), JNJ-63733657/posdinemab (J&J, phospho-tau), semorinemab (Roche/AC Immune), zagotenemab (Lilly, discontinued 2021), BIIB080 (Biogen/Ionis anti-tau ASO), and MK-1942 (Merck, O-GlcNAcase inhibitor). Beyond tau and amyloid, additional mechanisms under development include anti-inflammatory approaches (TREM2 agonists from Denali/AbbVie and Alector's AL002), synaptic modulators, and ApoE-targeted therapies. Sanofi's licensing of ADEL-Y01 positions it in a differentiated acetylated-tau niche, competing against phospho- and MTBR-tau approaches with a distinct epitope strategy that could deliver a cleaner safety profile.